The company's product is therapeutically equivalent to Otsuka Pharmaceutical Co's reference listed drug product Rexulti tablets, it added. ...

Pretomanid is the third TB drug to have been approved by the USFDA in the last 40 years.

Pretomanid, a new chemical entity, was under development since 2002 by the TB Alliance.

Hexaware Technologies is a midcap company, operating in information technology sector.

BDR clocked Rs 550-600 crore in revenue and around Rs 120 crore in FY18 EBITDA.

The drugs –– Bedaquiline by US drugmaker J&J and Delamanid by Japanese drugmaker Otsuka Pharma –– are the only treatment option for patient...

The business is expected to be valued at over $500 million and may also attract interest from a Chinese drugmaker and some Indian pharma co...

Interestingly, the growth came during the period when biggies like Sun Pharma and Dr Reddy's had reduced filings from their plants due to c...

Shares of Aurobindo Pharma climbed five per cent today as the company has received final approval from the US health regulator FDA to manuf...

Japanese firm Otsuka Pharmaceuticals, Myers-Squibb, Novartis are deferring launch of medicines critical for treatment of serious non-commun...

Claris will continue to hold a 20 per cent stake in the JV, while Otsuka and Mitsui will hold 60 and 20 per cent in it, respectively, a com...

The government today said it has approved 12 FDI proposals, including that of pharma firm Claris Otsuka, totalling over Rs 2,609 crore.

Buyout fund Carlyle had shown interest in buying the company and had even valued it at about Rs 3,800 crore.

Ahmedabad-based Claris Lifesciences Limited, India executed agreements for a Joint Venture with two Japan-based drug makers Otsuka Pharmace...

Shares of Claris have rallied 165 per cent from the start of the year and are currently trading at their lifetime high.

Ranbaxy Laboratories, India’s largest pharma company by sales, is looking to shift its marketing and administrative teams from its Gurgaon ...

The patent office in Mumbai has rejected Wockhardt’s application for a product patent for its product - nadifloxacin - a topical antibiotic...